Active Cancer NIHR-supported project Brain & Nervous System

BCMA/CD19 targeting CAR T cell for AL Amyloid: Phase 1 trial assessing the treatment of AL Amyloid (relapsed/refractory to previous therapy) with CAR T cells

Funder NIHR (part of DHSC)
Recipient organisation NIHR University College London Hospitals Biomedical Research Centre
NIHR support Recorded as supported by this research centre
Period Jan 2025 — Dec 2026

About this grant

This summary is based on the grant title only — the full abstract was not available.

No substantive source abstract was published for this research project funded by NIHR.

Researchers

Lydia Lee (Principal Investigator)

Related Research

Grants with similar aims, by meaning.

An open label, Phase 1 study evaluating the activity of Modular CAR T for myeloma
CRUKD/23/001 A Cancer Research UK First in Human Phase I/II trial of Aleta001, a first in class CD19-CD20 bridging protein, in patients who do not achieve or maintain an optimal response to anti-CD19 CAR T cell therapy for the treatment of B cell malignancies
A Phase II study of PHE885, B-cell maturation Antigen (BCMA)-directed CAR-T cells in adult participants with relapsed and refractory multiple myeloma.
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of BMS-986393, a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Subjects with Relapsed or Refractory and lenalidomide-refractory Multiple Myeloma
An open-label, multi-centre, phase Ib/II study evaluating the safety and efficacy of Auto1, a CAR T cell treatment targeting CD19, in adult patients with relapsed or refractory B cell acute lymphoblastic leukaemia

Original classification

Cancer

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.